IBDEI3E6 ; ; 19-NOV-2015
 ;;3.0;IB ENCOUNTER FORM IMP/EXP;;JUN 29, 2015
 Q:'DIFQR(358.3)  F I=1:2 S X=$T(Q+I) Q:X=""  S Y=$E($T(Q+I+1),4,999),X=$E(X,4,999) S:$A(Y)=126 I=I+1,Y=$E(Y,2,999)_$E($T(Q+I+1),5,99) S:$A(Y)=61 Y=$E(Y,2,999) X NO E  S @X=Y
Q Q
 ;;^UTILITY(U,$J,358.3,57034,1,3,0)
 ;;=3^DM Type 1 w/ Foot Ulcer
 ;;^UTILITY(U,$J,358.3,57034,1,4,0)
 ;;=4^E10.621
 ;;^UTILITY(U,$J,358.3,57034,2)
 ;;=^5002616
 ;;^UTILITY(U,$J,358.3,57035,0)
 ;;=E10.622^^264^2849^85
 ;;^UTILITY(U,$J,358.3,57035,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,57035,1,3,0)
 ;;=3^DM Type 1 w/ Skin Ulcer
 ;;^UTILITY(U,$J,358.3,57035,1,4,0)
 ;;=4^E10.622
 ;;^UTILITY(U,$J,358.3,57035,2)
 ;;=^5002617
 ;;^UTILITY(U,$J,358.3,57036,0)
 ;;=E10.630^^264^2849^84
 ;;^UTILITY(U,$J,358.3,57036,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,57036,1,3,0)
 ;;=3^DM Type 1 w/ Peridontal Disease
 ;;^UTILITY(U,$J,358.3,57036,1,4,0)
 ;;=4^E10.630
 ;;^UTILITY(U,$J,358.3,57036,2)
 ;;=^5002619
 ;;^UTILITY(U,$J,358.3,57037,0)
 ;;=E10.641^^264^2849^82
 ;;^UTILITY(U,$J,358.3,57037,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,57037,1,3,0)
 ;;=3^DM Type 1 w/ Hypoglycemia w/ Coma
 ;;^UTILITY(U,$J,358.3,57037,1,4,0)
 ;;=4^E10.641
 ;;^UTILITY(U,$J,358.3,57037,2)
 ;;=^5002621
 ;;^UTILITY(U,$J,358.3,57038,0)
 ;;=E10.649^^264^2849^83
 ;;^UTILITY(U,$J,358.3,57038,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,57038,1,3,0)
 ;;=3^DM Type 1 w/ Hypoglycemia w/o Coma
 ;;^UTILITY(U,$J,358.3,57038,1,4,0)
 ;;=4^E10.649
 ;;^UTILITY(U,$J,358.3,57038,2)
 ;;=^5002622
 ;;^UTILITY(U,$J,358.3,57039,0)
 ;;=E10.65^^264^2849^81
 ;;^UTILITY(U,$J,358.3,57039,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,57039,1,3,0)
 ;;=3^DM Type 1 w/ Hyperglycemia
 ;;^UTILITY(U,$J,358.3,57039,1,4,0)
 ;;=4^E10.65
 ;;^UTILITY(U,$J,358.3,57039,2)
 ;;=^5002623
 ;;^UTILITY(U,$J,358.3,57040,0)
 ;;=E11.40^^264^2849^90
 ;;^UTILITY(U,$J,358.3,57040,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,57040,1,3,0)
 ;;=3^DM Type 2 w/ DM Neuropathy,Unspec
 ;;^UTILITY(U,$J,358.3,57040,1,4,0)
 ;;=4^E11.40
 ;;^UTILITY(U,$J,358.3,57040,2)
 ;;=^5002644
 ;;^UTILITY(U,$J,358.3,57041,0)
 ;;=E11.42^^264^2849^93
 ;;^UTILITY(U,$J,358.3,57041,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,57041,1,3,0)
 ;;=3^DM Type 2 w/ DM Polyneuropathy
 ;;^UTILITY(U,$J,358.3,57041,1,4,0)
 ;;=4^E11.42
 ;;^UTILITY(U,$J,358.3,57041,2)
 ;;=^5002646
 ;;^UTILITY(U,$J,358.3,57042,0)
 ;;=E11.43^^264^2849^86
 ;;^UTILITY(U,$J,358.3,57042,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,57042,1,3,0)
 ;;=3^DM Type 2 w/ DM Autonomic Polyneuropathy
 ;;^UTILITY(U,$J,358.3,57042,1,4,0)
 ;;=4^E11.43
 ;;^UTILITY(U,$J,358.3,57042,2)
 ;;=^5002647
 ;;^UTILITY(U,$J,358.3,57043,0)
 ;;=E11.49^^264^2849^88
 ;;^UTILITY(U,$J,358.3,57043,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,57043,1,3,0)
 ;;=3^DM Type 2 w/ DM Neurological Complications
 ;;^UTILITY(U,$J,358.3,57043,1,4,0)
 ;;=4^E11.49
 ;;^UTILITY(U,$J,358.3,57043,2)
 ;;=^5002649
 ;;^UTILITY(U,$J,358.3,57044,0)
 ;;=E11.51^^264^2849^91
 ;;^UTILITY(U,$J,358.3,57044,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,57044,1,3,0)
 ;;=3^DM Type 2 w/ DM Peripheral Angiopathy w/o Gangrene
 ;;^UTILITY(U,$J,358.3,57044,1,4,0)
 ;;=4^E11.51
 ;;^UTILITY(U,$J,358.3,57044,2)
 ;;=^5002650
 ;;^UTILITY(U,$J,358.3,57045,0)
 ;;=E11.52^^264^2849^92
 ;;^UTILITY(U,$J,358.3,57045,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,57045,1,3,0)
 ;;=3^DM Type 2 w/ DM Peripheral Angiopathy w/ Gangrene
 ;;^UTILITY(U,$J,358.3,57045,1,4,0)
 ;;=4^E11.52
 ;;^UTILITY(U,$J,358.3,57045,2)
 ;;=^5002651
 ;;^UTILITY(U,$J,358.3,57046,0)
 ;;=E11.610^^264^2849^89
 ;;^UTILITY(U,$J,358.3,57046,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,57046,1,3,0)
 ;;=3^DM Type 2 w/ DM Neuropathic Arthropathy
 ;;^UTILITY(U,$J,358.3,57046,1,4,0)
 ;;=4^E11.610
 ;;^UTILITY(U,$J,358.3,57046,2)
 ;;=^5002653
 ;;^UTILITY(U,$J,358.3,57047,0)
 ;;=E11.620^^264^2849^87
